We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-12.58%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$43.6B
AUM Growth
-$9.03B
(-17%)
Cap. Flow
-$1.48B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
21.41%
Holding
1,190
New
110
Increased
278
Reduced
409
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$364M |
| 2 |
SIVB
SVB Financial Group
SIVB
|
+$155M |
| 3 |
Textron
TXT
|
+$103M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$102M |
| 5 |
Sanofi
SNY
|
+$96.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$333M |
| 2 |
ExxonMobil
XOM
|
+$242M |
| 3 |
Dollar Tree
DLTR
|
+$231M |
| 4 |
Nutrien
NTR
|
+$213M |
| 5 |
National Vision
EYE
|
+$198M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.53% |
| 2 | Healthcare | 17.73% |
| 3 | Financials | 14.85% |
| 4 | Consumer Discretionary | 9.35% |
| 5 | Industrials | 8.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
801
Norwegian Cruise Line
NCLH
$9.25B
| $4.85M | 0.01% |
436,500
+1,200
| +0.3% | +$20.1K |
|
802
Finance of America Companies
FOA
$211M
| $4.71M | 0.01% |
299,998
+85,445
| +40% | +$1.97M |
|
|
SAIL
803
DELISTED
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
| $4.7M | 0.01% |
+75,000
| New | +$4.63M |
|
|
DISH
804
DELISTED
DISH Network Corp.
DISH
| $4.68M | 0.01% |
261,120
-5,000
| -2% | -$121K |
|
805
Molson Coors Class B
TAP
$7.9B
| $4.6M | 0.01% |
84,436
-112,300
| -57% | -$6.03M |
|
806
Amphenol
APH
$211B
| $4.56M | 0.01% |
141,602
-897,000
| -86% | -$31.2M |
|
807
Tango Therapeutics
TNGX
$4.78B
| $4.53M | 0.01% |
1,000,000
| – | – |
|
808
Energy Vault
NRGV
$589M
| $4.48M | 0.01% |
446,911
-453,089
| -50% | -$5.89M |
|
809
Fox Class B
FOX
$22.1B
| $4.47M | 0.01% |
150,565
-6,100
| -4% | -$198K |
|
810
Ralph Lauren
RL
$22.5B
| $4.32M | 0.01% |
+48,226
| New | +$4.87M |
|
811
Arq
ARQ
$88.4M
| $4.31M | 0.01% |
919,900
| – | – |
|
812
Praxis Precision Medicines
PRAX
$8.66B
| $4.3M | 0.01% |
117,069
+64,264
| +122% | +$6.86M |
|
813
Bath & Body Works
BBWI
$4.25B
| $4.28M | 0.01% |
158,905
-81,976
| -34% | -$3.56M |
|
814
East-West Bancorp
EWBC
$18.2B
| $4.26M | 0.01% |
65,733
+40,000
| +155% | +$2.87M |
|
815
Collegium Pharmaceutical
COLL
$1.16B
| $4.25M | 0.01% |
+240,000
| New | +$4.04M |
|
816
Design Therapeutics
DSGN
$827M
| $4.2M | 0.01% |
300,000
+100,000
| +50% | +$1.35M |
|
817
uniQure
QURE
$3.04B
| $4.19M | 0.01% |
225,000
-475,000
| -68% | -$7.56M |
|
818
Highwoods Properties
HIW
$3.64B
| $4.17M | 0.01% |
121,985
+48,947
| +67% | +$1.93M |
|
819
Waste Management
WM
$90B
| $4.09M | 0.01% |
26,762
-74,341
| -74% | -$11.6M |
|
820
Werewolf Therapeutics
HOWL
$19.9M
| $4.09M | 0.01% |
1,000,597
+25,000
| +3% | +$114K |
|
821
Roivant Sciences
ROIV
$24.9B
| $4.07M | 0.01% |
+1,000,000
| New | +$3.97M |
|
822
PVH
PVH
$4.1B
| $4M | 0.01% |
+70,343
| New | +$4.86M |
|
823
Marqeta
MQ
$1.89B
| $4M | 0.01% |
123,294
-129,186
| -51% | -$5.08M |
|
|
KZR
824
DELISTED
Kezar Life Sciences
KZR
| $3.97M | 0.01% |
48,000
-138,485
| -74% | -$12.2M |
|
825
Liquidia Corp
LQDA
$7.82B
| $3.92M | 0.01% |
+900,000
| New | +$4.65M |
|
Similar funds
Adage Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Adage Capital Partners held 1,190 positions worth $43.6B, down 17% from $52.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners withdrew a net $1.48B in Q2 2022, closing 115 positions and reducing 409 holdings. Its most notable exit was Nutrien, an estimated $213M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Booz Allen Hamilton worth $75.6M.
- Adage Capital Partners's largest Q2 2022 buy was Booz Allen Hamilton: 837,064 shares worth $75.6M.
- Adage Capital Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, an estimated $364M increase.
- Adage Capital Partners's biggest Q2 2022 reduction was Royalty Pharma, cutting an estimated $333M.
- Adage Capital Partners fully exited Nutrien in Q2 2022, selling an estimated $213M.
- Adage Capital Partners's ten largest holdings make up 21% of its $43.6B portfolio in Q2 2022.
- Adage Capital Partners opened 110 new positions and closed 115 in Q2 2022.
- Adage Capital Partners's portfolio value fell 17% quarter-over-quarter to $43.6B.
Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.